A patent-protected, cash-rich “ingredient brand” enabling shipping decarbonization—mispriced due to EU regulatory overhang and customer de-stocking shock.
Overview
I-Tech AB (ITECH.ST) is a Swedish, specialized biotech/chemical “ingredient supplier” commercializing Selektope®, a patented antifouling agent (medetomidine) that prevents barnacle settlement through a targeted, non-lethal receptor mechanism rather than heavy-metal toxicity. By keeping hulls smoother, Selektope reduces hydrodynamic drag and fuel burn, aligning directly with shipping’s decarbonization and cost-reduction imperatives. The company is asset-light: it outsources pharmaceutical-grade synthesis of medetomidine and sells/licences the ingredient to leading global marine coating manufacturers, who blend it at very low concentrations into their own paints. Its customer roster includes multiple top-tier paint makers (six of the nine largest globally), with end-market deployment heavily concentrated in Asia-Pacific shipbuilding and drydock hubs (China, South Korea, Japan). Beyond commercial vessels, I-Tech is exploring adjacent markets such as leisure boats and aquaculture infrastructure as copper restrictions and demand for metal-free antifouling solutions expand. Overall, the company sits at the intersection of marine biology, specialty chemicals, and maritime emissions reduction, with value derived from IP ownership, regulatory approvals, and deep partnerships with coating formulators.